Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
| Mar '26 | Sep '25 | Mar '25 | Sep '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
3.86 | 2.93 | 2.99 | 2.46 |
+2 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
7.34% | 18.89% | 19.99% | 14.16% | |
Debt/Equity |
0.10 | 0.35 | 0.38 | 0.27 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.41) | (0.90) | (0.92) | (3.12) | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(0.79) | (0.29) | 0.50 | 0.65 | |
Working Capital |
9.14 | 5.83 | 5.81 | 5.28 | |
Capital Expenditures |
(0.04) | (0.04) | (0.07) | (0.11) | |
Net Current Asset Value |
9.07 | 4.37 | 4.30 | 4.07 | |
| Other line items | |||||
Quick Ratio |
3.75 | 2.73 | 2.80 | 1.71 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
8.37 | 3.91 | — | — | |
Average Payables |
1.15 | 1.39 | — | — | |
Average Inventory |
0.65 | 0.39 | — | — | |
Average Assets |
10.76 | 6.52 | — | — | |
Average Common Equity |
6.92 | 2.86 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates